Citi said Aurobindo Pharma's management commentary was underwhelming, with high single-digit growth expectations in the ...

Aurobindo Pharma on Monday reported a marginal dip in its consolidated profit after tax to Rs 903 crore for the fourth ...

Shares of Aurobindo Pharma Ltd fell 2.5 percent to Rs 1,161 in morning trade on May 28 after the company reported an 11 ...

In Q4FY25, the company's revenue from operations rose by 10.6 per cent year on year to ₹8,382 crore, with growth across its ...

The company delivered healthy top-line growth in Q4 FY25, though bottom-line fell short of CNBC-TV18 poll expectations.

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1440 in ...

Aurobindo Pharma's net profit declines slightly, but revenue and total expenses show significant growth in March quarter.

Aurobindo Pharma experienced a slight dip in Q4FY25 net profit, despite a revenue increase. However, the company saw ...

Aurobindo Pharma is estimated to report a 9.4% jump in consolidated revenue at Rs 8,197 crore. KEC International is estimated ...

March quarter results reveal mixed performance across sectors. Banking and IT experienced muted profit growth, while pharma ...

Aurobindo Pharma reported a slight decline in its consolidated profit after tax to Rs 903 crore for the fourth quarter ended March 2025. Revenue grew to Rs 8,382 crore.